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Eteplirsen, a compound designed to restore dystrophin in patients with Duchenne muscular dystrophy, 
controversially received approval by the FDA in 2016. Owing to limited clinical data, the approval was 
based on eteplirsen’s effect on dystrophin expression. Now, the dystrophin quantification results have 
been published and although low levels of dystrophin expression are shown, the quantification remains 
debatable.  
Refers to Charleston, J. S. et al. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and 
dystrophin production. Neurology, https://dx.doi.org/10.1212/WNL.0000000000005680 (2018). 
Duchenne muscular dystrophy (DMD) is a fatal, X-linked progressive muscle-wasting disease caused by 
mutations (generally large deletions) that abolish production of dystrophin. This protein links the 
cytoskeleton to the extracellular matrix of muscle fibers and so protects them from being damaged during 
contraction. Deletions that are located in the middle of the gene and maintain the reading frame allow 
the production of short, partially functional dystrophin proteins. These ‘pseudodystrophins’ are 
associated with Becker muscular dystrophy (BMD), a muscular dystrophy that has a later onset and a 
slower disease progression than DMD, with near-normal life expectancy. 
Eteplirsen is a so-called exon-skipping drug. The exon-skipping approach aims to manipulate the splicing 
of dystrophin transcripts in patients with DMD such that the reading frame is restored, enabling these 
patients to produce BMD-like pseudodystrophins. The approach is mutation specific, as the size and 
location of the deletion dictates the exon to be targeted by the therapy. Eteplirsen’s therapeutic 
mechanism of exon 51 skipping is applicable to ~14% of patients with DMD.  
Eteplirsen was approved under the accelerated approval pathway, which facilitates the approval of agents 
for serious or life-threatening diseases, enabling patient access to new therapies while the company 
conducts clinical trials to verify the predicted clinical benefit. The approval was based on a study done in 
12 patients without a placebo control. Although the sponsor (Sarepta Therapeutics) argued that eteplirsen 
treatment resulted in a reduced disease progression in treated patients compared with natural history 
data, the FDA did not accept this finding as proof of any functional effects. However, FDA granted 
accelerated approval on the basis of the surrogate endpoint of dystrophin increase in skeletal muscle and 
Sarepta was requested to provide data confirming functional effects by 2021 as part of the conditions of 
the accelerated approval1. 
In a new paper, published 18 months after the approval, Charleston et al.2 report the quantification of 
dystrophin in the biopsies collected in the eteplirsen trial. Patients were first treated for 24 weeks with 
placebo or eteplirsen (30 mg/kg or 50 mg/kg) via weekly intravenous infusion. However, after 24 weeks 
the four patients who received placebo were included in the treated cohorts and an open label trial was 
run for over 3 years. Muscle biopsies were obtained from all patients before treatment, after 12 weeks 
(50 mg/kg dose and two placebo treated patients), 24 weeks (30 mg/kg dose and two placebo treated 
patients) and 48 weeks (all patients). During the discussions with the FDA, a fourth biopsy was collected 
after 180 weeks of treatment from 11 of 12 patients. 
Analysis of RNA extracted from these biopsies by reverse transcription PCR (RT-PCR) confirmed exon 51 
skipping at the RNA level in all biopsies. However, RT-PCR can only confirm eteplirsen’s mechanism of 
action, which might not be accompanied by dystrophin expression. To confirm dystrophin expression, 
several methods were used (FIG. 1): western blotting and two immunofluorescence analysis methods, 
one in which dystrophin-positive fibers were counted subjectively in a blinded fashion in samples from 
treated patients and another that used an automated digital image analysis system. 
Immunohistochemical analysis of muscle sections revealed dystrophin-positive fibres in muscle from 
patients treated for at least 24 weeks. Following suggestions from the FDA, a quantitative western blot 
was set up3. Notably, this undertaking is no mean feat, as dystrophin is a notoriously difficult protein to 
quantify, owing to its low abundance and high molecular weight4.  
Unfortunately, dystrophin quantification, particularly by western blotting, requires large amounts of 
sample and sufficient residual sample was available from the pretreatment biopsies of only three patients, 
so the investigators decided to use muscle biopsies from nine other patients with deletions treatable with 
eteplirsen as baseline samples. Western blot analysis showed that the levels of dystrophin in untreated 
patients varied between undetectable and 0.37%, whereas the levels after treatment varied between 
undetectable and 2.47%. Dystrophin was undetectable in the samples from six of nine untreated patients, 
whereas it was undetectable in the samples from only two of 11 treated patients. On average dystrophin 
expression was 0.93% in samples from treated individuals and 0.08% in untreated individuals. 
Immunohistochemical analysis of biopsies showed that the average fluorescence intensity in arbitrary 
units was 9.41 for the untreated patients and 22. for the treated patients, whereas the mean number of 
positive fibres was 1.12% and 17.39% for untreated and treated patients, respectively.  
Consequently, it is very likely that eteplirsen induced an increase in dystrophin expression; however, we 
do not consider it to be possible to accurately quantify this increment with the data provided. The authors 
claim an 11.6-fold increase in dystrophin levels, which sounds very impressive. We would argue, however, 
that this claim is unsubstantiated. Most patients with DMD produce some dystrophin and these levels 
vary between patients5. As such, it is not possible to determine the fold-increases in the levels of 
dystrophin when baseline levels are not available (which was true for the majority of patients in this study) 
or below the lower limit of quantification (which was true all patients from whom pretreatment biopsy 
material was available). Furthermore, the lower limit of quantification of the assay is 0.25% dystrophin3, 
but the authors nevertheless used levels below this value detected in unrelated patients to quantify fold 
increases. Only three of the patients had pre-treatment and post-treatment biopsies that could provide 
acceptable data: these individuals all show an increase of dystrophin expression by 
immunohistochemistry (from 7.4-16.3 to 26.7-32.5 arbitrary units), which corresponds to a very small 
amount of dystrophin. 
The clinical relevance of this increase is debatable and this issue probably underlies the reticence of the 
European Medicines agency (EMA) to follow the FDA’s lead and approve eteplirsen in Europe. There are 
arguments for and against the benefit of very small levels of dystrophin. Within the past few years, it has 
become clear that patients who produce low levels of dystrophin from birth have a slower disease 
progression than those who produce dystrophin levels below the detection limit, and in a mouse model 
of severe DMD, dystrophin levels below 4% were sufficient to increase median survival from ~3 months 
to ~7 months6. However, these patients and mice produced these dystrophin levels from birth. Whether 
restoration of dystrophin in patients with DMD at these levels but at a later time-point will result also in 
a slower disease progression remains to be confirmed.  
Several confirmatory studies to test functional effects of eteplirsen treatment are ongoing and will 
hopefully solve questions about eteplirsen’s clinical use. If these clinical results are still unclear, validated 
and stringent dystrophin quantification methods might facilitate the evaluation of these agents, but will 
require of the use of pre-treatment and post-treatment biopsies.  
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